Evaluation of a strain Long human respiratory syncytial virus with M2–2 gene deletion in intranasally vaccinated BALB/c mice - Scorecard - MDSpire

Evaluation of a strain Long human respiratory syncytial virus with M2–2 gene deletion in intranasally vaccinated BALB/c mice

  • By

  • Ri-gan Shu

  • Jie Jun

  • Yun-xuan Zheng

  • Dan-ning Yue

  • Hao Hu

  • Hua-wei Xu

  • Xiao-lei Zhao

  • Hong-ru Wang

  • Xi-man Liu

  • Yi-peng Zhang

  • He Wang

  • Jie-mei Yu

  • Yan-peng Zheng

  • Xiang-lei Peng

  • Yuan-hui Fu

  • Jin-sheng He

  • June 8, 2026

  • 0 min

Share

Clinical Scorecard: Assessment of a Long Human Respiratory Syncytial Virus Strain Lacking the M2–2 Gene in BALB/c Mice Following Intranasal Vaccination

At a Glance

CategoryDetail
Condition
Key MechanismsDeletion of M2-2 gene enhances gene transcription and protein expression, significantly reducing viral replication.
Target Population
Care Setting

Key Highlights

  • M2-2 deletion strategy demonstrated robust immune responses in BALB/c mice, including Th1-biased immune profiles.

Guideline-Based Recommendations

Diagnosis

    Management

    • Live-attenuated vaccines are the only acceptable approach for pediatric RSV vaccination, with ongoing trials for new formulations.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Current RSV vaccines are not available for infants aged 6 months to 5 years, but recent vaccines have been approved for older populations.

        Clinical Best Practices

        • Conduct thorough safety evaluations in clinical trials to monitor for ERD, including specific monitoring protocols.

        Related Resources & Content

        Original Source(s)

        Related Content